Understand the source comparison
Comparative Dosing: DSIP vs Other Analgesic Peptides
DSIP 150–500mcg SC/IV Opioid receptor sensitisation, substance P inhibition 30–90 min (SC), 10–20 min (IV) 4–8 hours acute; cumulative over weeks High. Widely synthesised Best for chronic pain potentiation; requires consistent dosing schedule for sustained ben
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- DSIP
- 150–500mcg SC/IV
- Opioid receptor sensitisation, substance P inhibition
- 30–90 min (SC), 10–20 min (IV)
- 4–8 hours acute; cumulative over weeks
- High. Widely synthesised
- Best for chronic pain potentiation; requires consistent dosing schedule for sustained benefit
- BPC-157
- 200–500mcg SC daily
- Tissue repair signalling, VEGF upregulation
- 2–4 hours
- Sustained over 12–24 hours
- High. Stable peptide
- Best for injury-related pain with inflammatory component; analgesic effect is secondary to repair
- Thymosin Beta-4
- 2–10mg SC 2x/week
- Anti-inflammatory cytokine modulation
- 6–12 hours
- 48–72 hours
- Moderate. Higher cost
- Best for systemic inflammation contributing to pain; dose requirements make it cost-prohibitive for many labs
- Selank
- 250–750mcg intranasal
- Anxiolytic, GABA modulation
- 15–30 min
- High. Nasal formulation common
- Best for pain with significant anxiety component; does not address nociceptive pathways directly
- Semax
- 300–600mcg intranasal
- BDNF upregulation, neuroprotection
- 20–40 min
- 3–6 hours
- High. Structurally stable
- Best for neuropathic pain; limited efficacy in musculoskeletal or visceral pain models